Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 10 Stocks With Easy 9-30% Upside.

Ocular Therapeutix rallied for a third straight session on Thursday, jumping 10.45 percent to close at $9.30 apiece, as investors continued to load up portfolios in anticipation of business updates from its participation in several conferences next week.

Chief Scientific Officer Jeffrey Heier and Chief Development Officer Peter Kaiser are set to present in a symposium at the 14th Annual Vit-Buckle Society (VBS) Meeting in Las Vegas, Nevada, on Saturday, April 11, Ocular Therapeutix Inc. (NASDAQ:OCUL) said. They are expected to discuss redefining the management of Neovascular AMD.

eyes

Photo by José Antonio Otegui Auzmendi on Pexels

Likewise, its Chairman, President, and CEO, Pravin Dugel, would present at the Congreso Nacional de Oftalmologia (CNO) 2026 in Buenos Aires, Argentina, next Wednesday, April 15, where he would tackle Tyrosine Kinase Inhibitors, as well as the current state of treatments for diabetic retinal disease and neovascular AMD.

Investors expect Ocular Therapeutix Inc. (NASDAQ:OCUL) to provide updates from its investigational drug, Axpaxli, which is currently being studied in a phase 3 trial for patients with wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

While we acknowledge the risk and potential of OCUL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OCUL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.